1. Home
  2. SHO vs IMCR Comparison

SHO vs IMCR Comparison

Compare SHO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SHO

Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

N/A

Current Price

$9.08

Market Cap

1.8B

ML Signal

N/A

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$36.67

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHO
IMCR
Founded
1995
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
SHO
IMCR
Price
$9.08
$36.67
Analyst Decision
Hold
Buy
Analyst Count
8
9
Target Price
$9.31
$67.00
AVG Volume (30 Days)
2.0M
307.4K
Earning Date
11-07-2025
11-06-2025
Dividend Yield
3.98%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$937,930,000.00
$379,590,000.00
Revenue This Year
$5.75
$32.31
Revenue Next Year
$5.65
$10.50
P/E Ratio
$911.21
N/A
Revenue Growth
3.04
28.11
52 Week Low
$7.45
$23.15
52 Week High
$12.27
$40.72

Technical Indicators

Market Signals
Indicator
SHO
IMCR
Relative Strength Index (RSI) 47.08 50.52
Support Level $9.00 $35.41
Resistance Level $9.23 $37.17
Average True Range (ATR) 0.15 1.71
MACD -0.00 -0.21
Stochastic Oscillator 51.02 24.54

Price Performance

Historical Comparison
SHO
IMCR

About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: